32.6 C
Vientiane
Wednesday, September 17, 2025
spot_img
Home Blog Page 29

AUKEY Releases MagFusion 1X: Fast, Stylish, and Affordable Qi2.2 Wireless Charging Stand

LOS ANGELES, Sept. 15, 2025 /PRNewswire/ — Global wireless charging leader AUKEY today announced the official release of MagFusion 1X, a sleek and affordable wireless charging stand for a single device. Designed for users who value fast, safe, and convenient charging without compromising on style, MagFusion 1X combines high-performance charging with modern aesthetics. Available in four trendy colors, it’s a versatile addition to any environment—from home and office to study spaces or bedside tables.

AUKEY MagFusion 1X Magnetic Wireless Charging Stand
AUKEY MagFusion 1X Magnetic Wireless Charging Stand

Fast and Reliable Charging
MagFusion 1X is Qi2.2-certified (also known as Qi2 25W), delivering up to 25W ultra-fast wireless charging for compatible devices. Compared with standard 15W Qi2 chargers, it can charge a phone to full power about 25 minutes faster, based on AUKEY lab tests using an iPhone 16 Pro Max. Strong magnetic alignment keeps devices securely in place throughout charging, ensuring more efficient power transfer.

Designed for Modern Use
The stand-style design supports hands-free operation, allowing users to charge and use their devices simultaneously. With adjustable angles up to 35°, it offers flexible viewing for video calls, streaming, or browsing. A vacuum silicone suction base adds anti-slip stability, preventing tipping or accidental displacement.

Fashion Meets Function
Available in Frost White, Dark Gray, Desert Gold, and Black, MagFusion 1X blends seamlessly with both home and office décor. Its stylish design makes it an ideal accessory for daily use—whether working, studying, or relaxing at home.

Availability
MagFusion 1X is available starting today in the U.S. via AUKEY’s official website for $28.99, delivering premium wireless charging at an affordable price.

For More Information
AUKEY official website: www.aukey.com
Media inquiries: pr@aukey.com 
Sales inquiries: b2b@aukey.com 

About AUKEY

AUKEY is a globally leading provider of cutting-edge consumer electronics designed for both practical performance and visual appeal. With a strong user-centric focus, AUKEY’s ever-expanding product portfolio creates a unique space where technology meets aesthetics. The brand’s MagFusion series of wireless charging products has earned multiple international accolades, including the iF Design Award and Red Dot Design Award, and continues to garner worldwide acclaim.

 

FutureCeuticals Files Lawsuit Against NeuroRush Owner for Patent Infringement over Alleged Copycat Ingredient

MOMENCE, Ill., Sept. 15, 2025 /PRNewswire/ — VDF FutureCeuticals, Inc. filed a lawsuit against Aura Scientific, asserting that its brain performance ingredient NeuroRush – an extract of whole coffee fruit – infringes multiple of FutureCeuticals’ patents covering technology relating to coffee fruit, including patents relating to the use of coffee fruit compositions to improve measures of cognitive performance. The lawsuit seeks monetary damages, a finding of willful infringement, and the complete cessation of sales of the infringing ingredient.

FutureCeuticals created the whole coffee fruit market segment and has owned patents covering extracts of whole coffee fruit for many years. Among its coffee fruit technology are patents related to coffee fruit compositions for brain performance discovered following multiple human clinical trials FutureCeuticals commissioned and then published.

“Aura Scientific’s ingredient NeuroRush offers nothing new, simply ‘piggybacking’ on FutureCeuticals’ renowned, robust science, and patented discoveries in the coffee fruit sector, with infringement as the clear consequence. Indeed, this is among the most open and willful infringements we’ve ever seen, harming not only us, but our many licensees currently selling products containing our genuine ingredients, CognatiQ® and NeuroFactor®,” J. Randal Wexler, FutureCeuticals’ Vice President & General Counsel shared.

Although FutureCeuticals’ lawsuit seeks to stop this infringement at its source with Aura Scientific, FutureCeuticals is committed to doing everything necessary to rid the market entirely of the infringing ingredient. Mr. Wexler continued, “At this point, we are left with no other option than to vigorously protect and defend our IP rights and the interests of our customers in court, to the fullest extent of the law.”

FutureCeuticals noted that several dietary supplement consumer brands, both large and small, have recently launched brands containing Aura Scientific’s NeuroRush in their formulations. Mr. Wexler concluded, “We encourage product manufacturers to carefully evaluate their decision to include the NeuroRush material in their products in light of FutureCeuticals’ clear IP rights. We take our obligations to protect our IP on behalf of ourselves and our customers very seriously.”

About VDF FutureCeuticals, Inc.
VDF FutureCeuticals, Inc. is a leader in the research, development, and manufacture of fruit, vegetable, and grain-based powders and extracts for the functional food, beverage, and dietary supplement markets. We unlock the synergistic power of plants through the discovery and research of innovative and nutritious plant-based ingredients. CognatiQ® and NeuroFactor® are available exclusively from FutureCeuticals. 

The Korea Industry Daily: Industrial AI EXPO 2025 Concludes, Marking Milestone in Korea’s AI-Driven Industrial Transformation

SEOUL, South Korea, Sept. 15, 2025 /PRNewswire/ — The first-ever Industrial AI EXPO wrapped up at COEX Magok Convention Center after a three-day run from September 3 to 5, positioning itself as a key platform for accelerating the adoption of artificial intelligence across Korea’s industrial sectors.

The first-ever Industrial AI EXPO wrapped up at COEX Magok Convention Center after a three-day run from September 3 to 5, positioning itself as a key platform for accelerating the adoption of artificial intelligence across Korea’s industrial sectors.
The first-ever Industrial AI EXPO wrapped up at COEX Magok Convention Center after a three-day run from September 3 to 5, positioning itself as a key platform for accelerating the adoption of artificial intelligence across Korea’s industrial sectors.

The exhibition brought together 133 companies across 320 booths, unveiling a wide range of industrial AI equipment and solutions for the first time. The event opened with a series of high-level activities, including a memorandum of understanding (MOU) on building a data-sharing ecosystem for manufacturing and a Minister of Trade, Industry and Energy Award ceremony, recognizing 25 individuals and organizations for their contributions to industrial digital transformation and AI utilization.

Government officials and industry leaders—including executives from HD Hyundai, LG CNS, Microsoft Korea, Dassault Systèmes, HP Korea, Salesforce, and major domestic institutions—attended the opening ceremony, underscoring collective commitment to advancing industrial AI.

Vertical AI Showcases and Technology Debuts

The expo highlighted 12 key industrial AI task areas, covering market forecasting, supply chain optimization, process control, predictive maintenance, safety, workforce training, and cybersecurity. Exhibitors demonstrated how AI can improve efficiency and resilience in manufacturing and beyond.

Notably, HD Hyundai shared AI adoption cases from shipbuilding and construction equipment, while debuting its broader AIX (AI Transformation) strategy. Robotics, on-device AI, and physical AI technologies also made their first appearances, reflecting the next phase of industrial automation.

Global players including Microsoft, Dassault Systèmes, HP, NVIDIA (with domestic partner Leaders Systems), and Salesforce joined with Korean partners to showcase AI-driven innovations in manufacturing, customer management, and design—expanding both domestic B2B pipelines and global collaboration opportunities.

Conferences, Forums, and Business Networking

Beyond the exhibition floor, the event hosted a series of programs designed to strengthen the industrial AI ecosystem:

  • Industrial AI Conference – case studies and business models from leading corporations
  • AI-Tech Seminars – new technology launches and commercialization success stories
  • 1:1 Business Matching – connecting suppliers with demand-side enterprises
  • Startup IR and Investment Networking – pitches, mentoring, and investor sessions
  • Industrial AI International Certification Forum – discussions on reliability, safety, and standards with global stakeholders

Visitors also participated in guided docent tours, LG Science Park programs, and interactive events that highlighted industrial AI use cases across physical AI, manufacturing AI, and AI agent domains.

Building Korea’s Industrial AI Ecosystem

Lee Gil-seon, Executive Managing Director of the Korea Smart Manufacturing Industry Association, emphasized:

“As the country’s first vertical AI exhibition, Industrial AI EXPO presented a wealth of successful application cases. By serving as a matching platform between supply and demand, the expo will accelerate the adoption of AI across industries, strengthen Korea’s industrial AI ecosystem, and enhance global competitiveness.”

The successful conclusion of the Industrial AI EXPO 2025 underscored Korea’s determination to leverage artificial intelligence not only as a technological tool but as a transformative driver of industrial innovation.

Sercomm Showcases Next-Gen RDK Video Accelerator STB Based on Broadcom BCM74116 at the RDK Global Summit 2025

AMSTERDAM, Sept. 15, 2025 /PRNewswire/ — At the RDK Global Summit, Sercomm Corporation (TWSE: 5388), a leading global provider of entertainment and broadband equipment, today introduced its newest RDK Video Accelerator based on the latest Broadcom BCM74116 integrated System on Chip (SoC). This new state-of-the-art STB will also use the latest RDK7 software release. 

RDK is an open-source software platform that standardizes core functions used in video and broadband devices. RDK enables service providers to control their device diagnostics data, business models, and apps to improve the customer experience and drive business results. The new Sercomm STB platform is designed to accelerate integration with operator user interfaces and video services, enabling speedier product launches, robust long-term support, and pre-integrated with several premium streaming apps. 

Sercomm’s RDK-7 Streamer with NPU
Sercomm’s RDK-7 Streamer with NPU

“Sercomm’s market innovation continues with the launch of their new RDK7-ready set-top box,” said Jason Briggs, President and GM of RDK. “As a Preferred Member of the RDK community, we’re very proud to see Sercomm’s ongoing commitment to serve our expansive operator community across the globe.”

“We are proud to announce our latest RDK Video Accelerator together with our partners Broadcom and RDK,” said Amir Mobini, Vice President of Global Product Marketing at Sercomm. “As a vertically-integrated, globally diverse OEM with a strong record as a leading shipper of RDK streaming set-top boxes worldwide, Sercomm stands ready to support operators who are looking for a set-top box platform solution based on the latest RDK architecture that can be quickly launched and tightly integrated into their subscriber services and offerings. This platform is one of the first of its kind to offer integrated edge AI powering a new wave of monetization opportunities for our operator partners.”

About Sercomm

Founded in 1992, Sercomm (TWSE: 5388) is a global leader in providing integrated networking and telecom solutions. Partnering with the world’s top service providers, system integrators, and leading technology companies, Sercomm’s expertise in designing and manufacturing innovative, customized solutions makes embedding connectivity more accessible across the globe.

For more information, please visit https://www.sercomm.com/

TCTM Kids IT Education Inc. Announces Name Change to VisionSys AI Inc.

BEIJING, Sept. 15, 2025 /PRNewswire/ — TCTM Kids IT Education Inc. (NASDAQ: VSA) (“VSA” or the “Company“), an emerging technology services company, specializing in brain machine interaction businesses leveraging the core algorithms and related software and hardware systems, is pleased to announce that it has changed its name to “VisionSys AI Inc” after receiving the Certificate of Incorporation on Change of Name from the Registry of Companies, Cayman Islands, on September 10, 2025. The change of name will be effective on Nasdaq on September 19, 2025. The Company’s ADSs will continue trading on the Nasdaq Capital Market under the trading symbol “VSA”, and the CUSIP number shall remain unchanged.

About VisionSys AI Inc (formerly known as TCTM Kids IT Education Inc.)

VSA is an emerging technology services company, specializing in brain machine interaction businesses leveraging the core algorithms and related software and hardware systems. We are dedicated to advancing AI-powered healthcare and biotech solutions that transform industries. Our mission is to empower individuals and organizations through intelligent systems, bridging innovation with real-world impact to create a smarter, more connected future.

Safe Harbor Statement

This announcement contains forward-looking statements made under the “safe harbor” provisions of Section 21E of the Securities Exchange Act of 1934, as amended, and the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as “will,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates,” “confident” and similar statements. Such statements are based upon management’s current expectations and current market and operating conditions, and relate to events that involve known or unknown risks, uncertainties and other factors, all of which are difficult to predict and many of which are beyond the Company’s control. Further information regarding these and other risks, uncertainties or factors is included in the Company’s filings with the U.S. Securities and Exchange Commission. The Company does not undertake any obligation to update any forward-looking statement as a result of new information, future events or otherwise, except as required under law.

For further information, please contact:

Investor Relations Contact
VisionSys AI Inc (formerly known as TCTM Kids IT Education Inc.)
Email:  info@visionsysai.com 

Biostar Pharma Successively Achieved First Patient Dosing for Two Phase II/III Multiregional Clinical Trials of Utidelone Capsule (UTD2)

SAN FRANCISCO, Sept. 15, 2025 /PRNewswire/ — Biostar Pharma, Inc., the US subsidiary of Beijing Biostar Pharmaceuticals Co., Ltd. (“Biostar”, Stock Code: 2563.HK) which is a synthetic biology driven biopharma company focusing on the discovery, development and commercialization of innovative oncology drugs, is pleased to announce that the first patients have been dosed for two phase II/III multiregional clinical trials (MRCT) of “Utidelone Capsule (UTD2) first-line treatment for locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma” (NCT06841679) and “UTD2 treatment for platinum-resistant advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer” (NCT07044349) on September 11, 2025 and September 12, 2025, respectively.

Utidelone has demonstrated excellent clinical data in gastric cancer: in a completed Phase II study of Utidelone Injection (UTD1) combined with PD-1 inhibitor and oxaliplatin for the first-line treatment of unresectable locally advanced or recurrent/metastatic HER2-negative gastric cancer, 23 patients had completed efficacy evaluation. Among them, 15 achieved partial response (PR) and 8 achieved stable disease (SD), resulting in a 65.2% objective response rate (ORR) and 100% clinical benefit rate (CBR). The median progression-free survival (mPFS) was 6.1 months. The combination regimen was generally well-tolerated. Most treatment-related adverse events (TRAEs) were Grade 1-2, reversible, and manageable. The longest treatment duration received by a patient was 22 cycles [1]. Consequently, Utidelone was granted an Orphan Drug Designation by the U.S. FDA for the treatment of advanced gastric cancer.

Besides gastric cancer, Utidelone has also shown considerable potential for treating ovarian cancer in previous clinical studies. A US Phase I clinical study of UTD2 as a monotherapy for advanced solid tumors had 12 evaluable patients, including one ovarian cancer patient with a complete response (CR) and another with PR, who had previously undergone 7 and 9 lines of therapy, respectively [2]. A Phase II clinical study of UTD1 as monotherapy for the treatment of advanced solid tumors had 10 evaluable patients in advanced ovarian cancer cohort, among them there were 1 PR and 3 SD.

Compared to taxanes, which are difficult for oral formulation development, Utidelone is not susceptible to P-glycoprotein thus cannot be pumped out of the cancer cell by P-glycoprotein and has the advantage for higher oral bioavailability and lower risk of developing cross-resistance. By utilizing its technology platform, Biostar developed Utidelone Capsule, and its efficacy and safety have been confirmed in both US and China’s studies. Utidelone Capsule will significantly improve the convenience of administration, compliance of patients, decrease in treatment cost and ease of combination therapy with other oral anti-cancer drugs, and more suitable for adjuvant or maintenance therapy. Beyond gastric and ovarian cancers, Biostar is actively planning and advancing multiple clinical studies to expand UTD2’s indications, including breast cancer adjuvant intensification therapy, pancreatic cancer, esophageal cancer, colorectal cancer, and so on.

About NCT06841679 Study

This study is a multi-national, open-label, randomized phase II/III clinical study of UTD2 combined with standard of care to evaluate the efficacy and safety in first-line patients with locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma, untreated with systemic treatment in the advanced setting. For the Phase II part, 78 subjects are planned to be enrolled in China, US, Europe and Japan. Its primary objectives are to evaluate the safety, efficacy, and pharmacokinetic profile of UTD2 in combination therapy. The Phase III part plans to enroll 700 subjects across multiple countries/regions. The primary endpoint is overall survival (OS), with secondary endpoints including PFS, ORR, and safety.

About NCT07044349 Study

This study is a multi-national, open-label, randomized Phase II/III clinical trial of UTD2 for the treatment of patients with platinum-resistant advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer. The Phase II part plans to enroll approximately 84 subjects. Its primary objective is to evaluate the safety, efficacy, and pharmacokinetic (PK) characteristics of UTD2 under different dosing regimens in the target patient population and to recommend a dose for Phase III. The Phase III part plans to enroll 480 subjects and is planned to be conducted in multiple countries and regions worldwide. Its primary objective is to evaluate the efficacy and safety of UTD2 compared to the investigator’s choice of standard treatment in the target patient population. The primary endpoint is PFS, with secondary endpoints including OS, ORR, and others.

About Utidelone

Utidelone is a new-generation genetically engineered microtubule inhibitor, and has similar mechanism of action with that of taxanes while demonstrating multiple advantages, including better anti-tumor activity, broader anti-tumor spectrum, better safety profile with very low hematologic toxicity, effective against multidrug-resistant tumors, less prone to developing drug resistance, capability of crossing the blood-brain barrier to prevent and treat brain tumors, and high oral bioavailability. Biostar has developed two formulations of Utidelone: injection (UTD1) and capsule (UTD2). UTD1 has been launched in China in 2021 for the treatment of metastatic breast cancer (MBC), who have progressed after at least one anthracycline- or taxane-containing chemotherapy regimen. The phase III study data showed that UTD1 plus capecitabine achieved both PFS and OS benefits versus capecitabine for heavily pretreated MBC patients, and the results were orally presented twice at ASCO annual meetings and published in prestigious journals [3-4].

About Biostar

Biostar is an integrated biopharma company focusing on the development of innovative anti-cancer drugs utilizing its synthetic biology R&D platform. The company is listed on the Hong Kong Stock Exchange (HK 2563) in 2024. We are actively selecting reliable global partners through out-licensing or co-development of Utidelone assets. We believe that our strong capabilities of R&D and manufacturing, coupled with our enriched commercial expertise, make us the preferred partner for global biopharmaceutical companies who share our goal of bringing innovative anti-cancer products to patients around the world. For additional information on partnering with Biostar, please contact our business development team at bd@biostar-pharma.com.

Reference
[1] 2025 ASCO Abstract #: 4040
[2] 2025 ASCO Abstract #: 3030
[3] B. Xu, T. Sun, Q. Zhang, et al. Annals of Oncology, 2021, 32(2): 218-228
[4] Pin Zhang, Tao Sun, Qingyuan Zhang, et al. Lancet Oncol 2017; 18: 371-83

First Phosphate Closes Follow-On Tranche of Oversubscribed Private Placement


Saguenay, Quebec – Newsfile Corp. – September 15, 2025 – First Phosphate Corp. (CSE: PHOS) (OTCQX: FRSPF) (FSE: KD0) (“First Phosphate” or the “Company“) is pleased to announce that on, September 12, 2025, it closed a subsequent tranche of its non-brokered private placement financing (the “Offering“), as further described in the Company’s news releases dated August 5, 2025 and August 25, 2025.

Under this tranche of the financing, the Company raised a total of $3.78 million through the issuance of 5,150,000 Flow-Through Shares for gross proceeds of $2.58 million and 2,415,000 Hard Dollar Units, comprised of 2,415,000 Common Shares and 1,207,500 Warrants, for gross proceeds of $1.21 million. In aggregate, under both tranches of the Offering, the Company has raised gross proceeds of $6.73 million through the issuance of 9,899,000 Flow-Through Shares for gross proceeds of $4.95 million, and through the issuance of 3,565,000 Hard Dollar Units for gross proceeds of $1.78 million.

Together with this Offering, the Company has raised to date a total of approximately $35.2 million in 9 management-led non-brokered private-placement financings since June 2022 of which approximately $14.9 million has been closed over the last 5 months.

The Company paid cash finder’s fees of and $36,000 issued 324,800 common shares and 396,800 Warrants to purchasers of Hard Dollar Units in the current tranche. In total, in connection with the Offering, the Company has paid $61,200 in cash finder’s fees, issued 543,120 compensation shares and advisory shares at a price of $0.50 per common share, and issued 665,520 Compensation Warrants, exercisable at a price of $0.50 per common share of the Company, until December 31, 2025, subject to an Accelerated Expiry Date. All securities issued under the Offering are subject to a four-month and one day statutory hold period in accordance with applicable securities laws. The Company intends to use the proceeds from the Offering as disclosed in the Company’s press release dated August 5, 2025. Capitalized terms used in this news release and not defined herein have the meanings given to them in the Company’s news release dated August 5, 2025. The Company intends to close one final tranche of the Offering on September 19, 2025.

This news release does not constitute an offer to sell or a solicitation of an offer to sell any of securities in the United States. The securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”) or any state securities laws and may not be offered or sold within the United States or to U.S. Persons unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration is available. Completion of the Offering is subject to certain conditions including, but not limited to, the receipt of all necessary approvals. There can be no assurance that any further securities will be sold under Offering.

About First Phosphate Corp.

First Phosphate (CSE: PHOS) (OTCQX: FRSPF) (FSE: KD0) is a mineral development company dedicated to producing high-purity phosphate for the LFP battery industry. The Company is committed to sustainable extraction and purification with a low anticipated carbon footprint. Its vertically integrated model connects phosphate mining directly into the supply chains of North American battery producers. First Phosphate’s flagship project, the Bégin-Lamarche Property in Saguenay-Lac-Saint-Jean, Quebec, contains rare igneous anorthosite rock that yields high-purity phosphate with minimal impurities.

For additional information, please contact:
Bennett Kurtz
Chief Financial Officer
bennett@firstphosphate.com
Tel: +1 (416) 200-0657

Investor Relations: investor@firstphosphate.com
Media Relations: media@firstphosphate.com
Website: www.FirstPhosphate.com

Follow First Phosphate:
Twitter: https://twitter.com/FirstPhosphate
LinkedIn: https://www.linkedin.com/company/first-phosphate

Forward-Looking Information and Cautionary Statements
This news release contains certain statements and information that may be considered “forward-looking statements” and “forward-looking information” within the meaning of applicable securities laws. In some cases, but not necessarily in all cases, forward-looking statements and forward-looking information can be identified by the use of forward-looking terminology such as “plans”, “targets”, “expects” or “does not expect”, “is expected”, “an opportunity exists”, “is positioned”, “estimates”, “intends”, “assumes”, “anticipates” or “does not anticipate” or “believes”, or variations of such words and phrases or statements that certain actions, events or results “may”, “could”, “would”, “might”, “will” or “will be taken”, “occur” or “be achieved” and other similar expressions. In addition, statements in this news release that are not historical facts are forward-looking statements, including, among other things: the Company’s planned exploration and production activities; the properties and composition of any extracted phosphate; the Company’s plans for vertical integration into North American battery supply chains; and the receipt of all necessary approvals.

These statements and other forward-looking information are based on assumptions and estimates that the Company believes are appropriate and reasonable in the circumstances, which may prove to be incorrect, include, but are not limited to, the various assumptions set forth herein and in the Company’s public disclosure record including the short form base prospectus dated June 5, 2024, and the receipt of all necessary approvals.

There can be no assurance that such statements will prove to be accurate, and actual results and future events could differ materially from those anticipated in such statements. There can be no assurance that any opportunity will be successful, commercially viable, completed on time or on budget, or will generate any meaningful revenues, savings or earnings, as the case may be, for the Company. In addition, the Company will incur costs in pursuing any particular opportunity, which may be significant. These factors and assumptions are not intended to represent a complete list of the factors and assumptions that could affect the Company and, though they should be considered carefully, should be considered in conjunction with the risk factors described in the Company’s other documents filed with the Canadian and United States securities authorities, including without limitation the “Risk Factors” section of the Company’s Management Discussion and Analysis dated January 29, 2025 and Annual Report on 20-F dated July 8, 2024, which are available on SEDAR+ at www.sedarplus.ca. Although the Company has attempted to identify factors that would cause actual actions, events or results to differ materially from those disclosed in the forward-looking information or information, there may be other factors that cause actions, events or results not to be as anticipated, estimated or intended. The Company does not undertake to update any forward-looking information, except in accordance with applicable securities laws.

The issuer is solely responsible for the content of this announcement.

About First Phosphate Corp.

Baidu Announces Completion of CNY4.4 Billion Offering of CNY-denominated Senior Notes

BEIJING, Sept. 15, 2025 /PRNewswire/ — Baidu, Inc. (NASDAQ: BIDU and HKEX: 9888 (HKD Counter) and 89888 (RMB Counter)), (“Baidu” or the “Company”), a leading AI company with strong Internet foundation, today announced the completion of its offering of CNY4.4 billion aggregate principal amount of 1.90% senior unsecured notes due 2029 (the “Notes”). The Notes were sold in offshore transactions outside the United States to certain non-U.S. persons (the “Notes Offering”) in reliance on Regulation S under the United States Securities Act of 1933, as amended (the “Securities Act”).

The Company intends to use the net proceeds from the Notes Offering for general corporate purposes, including repayment of certain existing indebtedness, payment of interest and general corporate purposes.

The Notes have not been and will not be registered under the Securities Act or any state securities laws. They may not be offered or sold in the United States or to, or for the account or benefits of, U.S. persons (as defined in Regulation S under the Securities Act) except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act.

The listing of and permission to deal in the Notes on The Stock Exchange of Hong Kong Limited (the “Hong Kong Stock Exchange”) is expected to become effective on September 16, 2025.

This announcement shall not constitute an offer to sell or a solicitation of an offer to purchase any securities, in the United States or elsewhere, and shall not constitute an offer, solicitation or sale of the securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful.

About Baidu

Founded in 2000, Baidu’s mission is to make the complicated world simpler through technology. Baidu is a leading AI company with strong Internet foundation, trading on Nasdaq under “BIDU” and HKEX under “9888”. One Baidu ADS represents eight Class A ordinary shares.

Safe Harbor Statement

This announcement contains forward-looking statements. These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as “will,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates,” “confident” and similar statements. Baidu may also make written or oral forward-looking statements in its periodic reports to the U.S. Securities and Exchange Commission (the “SEC”), in announcements made on the website of the Hong Kong Stock Exchange, in its annual report to shareholders, in press releases and other written materials and in oral statements made by its officers, directors or employees to third parties. Statements that are not historical facts, including but not limited to statements about Baidu’s beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. A number of factors could cause actual results to differ materially from those contained in any forward-looking statement, including but not limited to the following: Baidu’s growth strategies; its future business development, including development of new products and services; its ability to attract and retain users and customers; competition in the Chinese Internet search and newsfeed market; competition for online marketing customers; changes in the Company’s revenues and certain cost or expense items as a percentage of its revenues; the outcome of ongoing, or any future, litigation or arbitration, including those relating to intellectual property rights; the expected growth of the Chinese-language Internet search and newsfeed market and the number of Internet and broadband users in China; Chinese governmental policies relating to the Internet and Internet search providers, and general economic conditions in China and elsewhere. Further information regarding these and other risks is included in the Company’s annual report on Form 20-F and other documents filed with the SEC, and announcements on the website of the Hong Kong Stock Exchange. Baidu does not undertake any obligation to update any forward-looking statement, except as required under applicable law. All information provided in this announcement is as of the date of the announcement, and Baidu undertakes no duty to update such information, except as required under applicable law.